Amicus Therapeutics, Inc. (FOLD)
- Previous Close
10.54 - Open
10.40 - Bid 10.10 x 100
- Ask 10.14 x 100
- Day's Range
10.02 - 10.47 - 52 Week Range
9.70 - 14.57 - Volume
1,747,736 - Avg. Volume
3,046,225 - Market Cap (intraday)
2.985B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.51 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.75
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
amicusrx.comRecent News: FOLD
Performance Overview: FOLD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FOLD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FOLD
Valuation Measures
Market Cap
3.11B
Enterprise Value
3.27B
Trailing P/E
--
Forward P/E
72.99
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.79
Price/Book (mrq)
19.44
Enterprise Value/Revenue
8.19
Enterprise Value/EBITDA
-35.54
Financial Highlights
Profitability and Income Statement
Profit Margin
-37.96%
Return on Assets (ttm)
-6.12%
Return on Equity (ttm)
-107.04%
Revenue (ttm)
399.36M
Net Income Avi to Common (ttm)
-151.58M
Diluted EPS (ttm)
-0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
286.2M
Total Debt/Equity (mrq)
277.86%
Levered Free Cash Flow (ttm)
-25.89M